Molecular Partners AG ADR (MOLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has a cash flow conversion efficiency ratio of -0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.67 Million) by net assets ($80.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Molecular Partners AG ADR balance sheet quality to measure how much of total assets are equity-financed.
Molecular Partners AG ADR - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Molecular Partners AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Molecular Partners AG ADR earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Molecular Partners AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Partners AG ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TBI Motion Technology Co Ltd
TW:4540
|
-0.091x |
|
Rexon Industrial Corp Ltd
TW:1515
|
0.068x |
|
AB Klaipedos nafta
F:XIC
|
-0.143x |
|
Gia Lai Electricity JSC
VN:GEG
|
0.076x |
|
SKY Metals Ltd
AU:SKY
|
-0.040x |
|
CPE Technology Berhad
KLSE:5317
|
0.007x |
|
FineTek Co Ltd
TWO:4549
|
0.002x |
|
DYNACOR GROUP INC.
F:OA5
|
0.011x |
Annual Cash Flow Conversion Efficiency for Molecular Partners AG ADR (2013–2025)
The table below shows the annual cash flow conversion efficiency of Molecular Partners AG ADR from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Molecular Partners AG ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.33 Million | $-51.26 Million | -0.638x | -52.53% |
| 2024-12-31 | $141.64 Million | $-59.25 Million | -0.418x | -25.08% |
| 2023-12-31 | $176.43 Million | $-59.01 Million | -0.334x | -166.33% |
| 2022-12-31 | $235.17 Million | $118.57 Million | 0.504x | +159.47% |
| 2021-12-31 | $107.29 Million | $-90.95 Million | -0.848x | -213.61% |
| 2020-12-31 | $107.22 Million | $-28.98 Million | -0.270x | -1130.82% |
| 2019-12-31 | $54.14 Million | $-1.19 Million | -0.022x | +95.26% |
| 2018-12-31 | $91.70 Million | $-42.47 Million | -0.463x | -35.09% |
| 2017-12-31 | $116.73 Million | $-40.02 Million | -0.343x | -31.60% |
| 2016-12-31 | $135.79 Million | $-35.38 Million | -0.261x | -249.27% |
| 2015-12-31 | $151.79 Million | $26.50 Million | 0.175x | +328.68% |
| 2014-12-31 | $148.48 Million | $-11.33 Million | -0.076x | +72.91% |
| 2013-12-31 | $48.32 Million | $-13.61 Million | -0.282x | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more